Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
about
Managing risks in drug discovery: reproducibility of published findingsCLASPs link focal-adhesion-associated microtubule capture to localized exocytosis and adhesion site turnoverEssentials of oral cancerPodoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stabilityReproducibility: changing the policies and culture of cell line authenticationMatch criteria for human cell line authentication: where do we draw the line?Antitumor Activity of 2,9-Di-Sec-Butyl-1,10-PhenanthrolineMetabolic interrogation as a tool to optimize chemotherapeutic regimens.HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Establishment and genetic characterization of six unique tumor cell lines as preclinical models for sinonasal squamous cell carcinomaNADPH oxidases: a perspective on reactive oxygen species production in tumor biologyCombination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinomaPhosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasisFunctional kinomics identifies candidate therapeutic targets in head and neck cancerA comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.Prelude to oral microbes and chronic diseases: past, present and futureThe head and neck cancer cell oncogenome: a platform for the development of precision molecular therapiesHedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers.Human papillomavirus 16 oncoprotein regulates the translocation of β-catenin via the activation of epidermal growth factor receptorDevelopment and characterization of six new human papillary thyroid carcinoma cell lines.MEK inhibitor PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and exhibits anti-tumor activity in head and neck cancer.The p53-reactivating small molecule RITA induces senescence in head and neck cancer cellsEvolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer.Inhibition of Phosphatidylcholine-Specific Phospholipase C Interferes with Proliferation and Survival of Tumor Initiating Cells in Squamous Cell CarcinomaAMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab.Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screeningDrug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancersSTAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients.STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC CellsDevelopment and characterization of salivary adenoid cystic carcinoma cell line.Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer PatientsDecreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancerTMEM16A/ANO1 is differentially expressed in HPV-negative versus HPV-positive head and neck squamous cell carcinoma through promoter methylationEfficacy, long-term toxicity, and mechanistic studies of gold nanorods photothermal therapy of cancer in xenograft mice.JunB promotes cell invasion, migration and distant metastasis of head and neck squamous cell carcinoma.c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.
P2860
Q29964497-1ED6006C-0924-4B52-A190-C2ABC3720424Q54605341-FF612A72-30FA-40FA-8605-7D55FBE14E10Q54608098-94C1641F-921A-4DD9-AC83-CA5512C66C44Q54608099-5DA209A5-ECCE-490A-B59E-8B57A0D59AC6Q54608240-887F021D-E24D-403E-B4B6-BF5B0B2B6AE6Q54750547-878BD337-EF82-4C07-B90C-F0FEDD8EA4DAQ54752132-C4DCEC58-74DF-4267-BCD7-619B7F86171DQ54796499-63789EAA-FC30-4339-B82F-9FB9043CA0D8Q54796503-8985D46B-0E5C-4CCE-A6F6-EB9A41CB0AC6Q54799751-78A99CCE-B570-4095-9172-BEC5A2235EBFQ54808305-4A2E8558-EB71-49D1-9BB1-7E186247C5BEQ54808394-8FC68F29-5234-4E8E-8C54-CE55C1F284B2Q54814069-C942BD37-27A5-43F0-9978-E27325AA19D2Q54831001-72EC2548-1726-4740-B9B8-0BCDA1E2704BQ54831196-EC0AC95D-56B0-4419-B6CB-B6367B0F09F8Q54831201-3F0CDA37-5764-4C79-920D-C2C8EBF5199CQ54831419-5C8E3D9D-CF87-4230-AAE5-93298EF37A7EQ54833221-15136D77-52F6-4739-B12B-835C902DFAFEQ54889992-16E83CAE-C4DB-4D04-AAA8-8EB6745059F9Q54889993-381ACFDD-371D-4217-948A-061A76B2EB19Q54890135-2566BF7F-BA95-489E-826E-AF90C8A62991Q54896653-45C4AA17-F4C6-4605-9307-942DD1C58A40Q54896654-17C27F18-0D55-4A73-ABAA-23A88762C59CQ54896655-D9C0AE1B-7700-4B5B-896F-BB30FC2E4455Q54896657-4383638D-8B24-489B-A8A6-7CC23EBFC1FFQ54896658-46A4E291-ABBE-42BE-94B6-E5FFD60E3F06Q54898667-D1AC1834-CBDE-475C-844C-D043A7868370Q54898668-56E93114-D8AF-40FB-863D-FDBE858B97E7Q54898669-416BA9D2-334A-46D5-8643-A40800118CCDQ54898670-EF017F59-F6A1-438D-92ED-174995BE9657Q54898674-E2707DF8-FA7A-4973-A558-6DBBF513089CQ54898675-98DC0044-0623-40DA-B14D-5E8471B16D48Q54898676-AABB80F0-6739-456E-B306-53A97BE2CB44Q54899003-7B54CEC5-F077-448B-BD80-58FF178368A8Q54899267-03983A95-D175-463A-A984-8A4B362C69ADQ54899531-C7ECAC71-AE21-4193-A7AC-BFAAB43EC72CQ54899532-BDF617E6-1913-445E-89E6-43FE6BD4658EQ54904549-A7603756-F033-4BD3-BBAF-40C26A3848E2Q54904551-AB84ABE5-5812-49D2-B421-7AF3507892DCQ54904552-A89E32A6-DE8D-4A5D-A5E2-5944CE4C6124
P1343
Q24289508-5717B1A4-B774-47AC-A20B-F0B499E249E3Q24298210-5C3C2EE1-7FC3-4B16-AB3F-0CA4257727E8Q26776080-17C7DDFC-D94B-4FC4-8D60-0602423CB299Q27310083-E1D53987-0DAD-42D6-B81C-86DB3C169974Q27910523-54B940DE-6E9A-4A6C-9161-EB23C6919CBDQ27910530-E0DD3783-CA58-48FC-B37E-9A141E553F5BQ28468510-2474A19F-AB6A-4E97-A77F-777CABC5C60EQ33566853-E90861A9-D920-48D6-BEF2-D6CAEF8F86A0Q33568344-E9BDF810-FD2E-4A66-BB18-815F99902DD3Q33595483-430345DC-8EB9-4314-A678-C612763577E5Q33632660-0B98E8CD-A48E-4590-81A1-E10C175E3153Q33875560-C62370B7-BFA7-402B-A9BE-957CF3CA75B9Q33884709-CEB331D0-53FC-4E5B-BE45-7549346A1B7DQ34055936-29EE9EBD-EC5F-4673-A643-92FDF55254D6Q34458117-94AD761D-067E-439F-BD55-8D71446A2B30Q34468829-810829AA-1BEB-48F1-979D-A92FCB1EE60EQ34619156-8F390ABA-0D21-4749-84C0-8B0D08061D49Q34620099-38D202F3-0D6E-4011-AF8B-E730F2CF5891Q34944436-D24DC874-5A3C-4FAF-BB60-4F0C2D01E131Q35055107-B722C979-CCDA-4B8B-9B21-770B519642DEQ35197507-51C6034A-69C1-4E68-B7F1-0596170CCE0FQ35224002-86655C3B-926C-4A14-B217-9121FBB7C099Q35251779-52E27C97-5589-413A-B481-4E0558A0AD24Q35453467-F6008498-F4EA-4E1C-89B7-A175934DBBBAQ35510945-72FF2D1E-BA4F-411B-BA66-977AE5BF8520Q35589535-B21DEF59-1638-42DB-9AF2-2897F01240C0Q35786713-CE1E6F53-97C1-486F-AA33-D417A29158E1Q35793842-DA5EA0BB-DA73-4303-BE86-773936878721Q35797331-119A185D-F3E5-4D10-9011-9BB963021A8CQ35889525-198A7188-CF64-4D41-BD00-2733DE60B2AEQ35920773-2C51CA74-2DB5-47FA-98B1-EAEBB50B47CFQ36030906-AD3FEB73-090F-4A54-8FDE-77BD8450D774Q36069693-6158B815-917D-413D-8EE9-F69B88C28F74Q36149312-074F2D5E-0D3D-4A93-B934-20620BEA50B5Q36191292-0884781A-BA52-4C12-8C75-045EBDD53E7FQ36237514-BDEFFCC7-51B1-4CAE-AB94-30EC9E6A77DBQ36275370-A90D3F21-B809-45EE-AD0E-D6AD938073D2Q36327498-9092C762-4927-44DD-8B36-21ADC592F924Q36454432-84237CB0-4940-47FF-89A3-9C98CEBCD8FDQ36545205-EDAF92AC-8E2A-42BA-B73E-AD30C370170E
P2860
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Assembly and initial character ...... rse head and neck tumor sites.
@ast
Assembly and initial character ...... rse head and neck tumor sites.
@en
type
label
Assembly and initial character ...... rse head and neck tumor sites.
@ast
Assembly and initial character ...... rse head and neck tumor sites.
@en
prefLabel
Assembly and initial character ...... rse head and neck tumor sites.
@ast
Assembly and initial character ...... rse head and neck tumor sites.
@en
P2093
P2860
P4510
P50
P1476
Assembly and initial character ...... erse head and neck tumor sites
@en
P2093
David Sidransky
Erich M Sturgis
Gary L Clayman
Jeffrey N Myers
Nils Erik Heldin
Peter G Sacks
Reuben Lotan
Samar A Jasser
Thomas J Ow
P2860
P304
P356
10.1158/1078-0432.CCR-11-0690
P407
P577
2011-08-25T00:00:00Z